Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153342 | 0.92 | MMP1 (0.38) | SLC22A6MAPTLMNAMMP1MMP2 | |
| SCHEMBL9745593 | 0.88 | MMP1 (0.35) | SLC22A6MAPTLMNAMMP1MMP2 | |
| SCHEMBL451544 | 0.86 | SLC22A6 (0.39) | SLC22A6GPR84MAPTGABRR1LMNA | |
| SCHEMBL15153935 | 0.85 | GABRP (0.38) | SLC22A6GPR84MMP1MMP2MMP3 | |
| SCHEMBL15478217 | 0.84 | LMNA (0.36) | SLC22A6MAPTLMNAMMP1MMP2 | |
| SCHEMBL19821829 | 0.84 | TSHR (0.36) | SLC22A6MAPTMMP1MMP2MMP3 | |
| SCHEMBL23072789 | 0.82 | GABRR1 (0.43) | SLC22A6MAPTGABRR1LMNAMMP1 | |
| SCHEMBL6155095 | 0.82 | FAAH (0.36) | SLC22A6MAPTMMP1MMP2MMP3 | |
| SCHEMBL6154465 | 0.82 | MMP1 (0.32) | SLC22A6MAPTMMP1MMP2MMP3 | |
| SCHEMBL26363332 | 0.82 | LMNA (0.33) | SLC22A6MAPTLMNAMMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111518035-A | Rosuvastatin tert-butylamine salt and preparation method thereof | 安徽鼎旺医药有限公司 | 2020-08-11 | — | — | CN | claimed |
| US-8874019-B2 | Image forming method | KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) | 2014-10-28 | — | — | US | claimed |
| US-20130202336-A1 | IMAGE FORMING METHOD | KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) | 2013-08-08 | — | — | US | claimed |
| US-20230323022-A1 | POLYESTER AND MOLDED ARTICLE | CHANG CHUN PLASTICS CO., LTD. (TW) | 2023-10-12 | — | — | US | disclosed |
| US-11773266-B2 | Polymer, molded body, foam, resin composition, and production method for polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-10-03 | — | — | US | disclosed |
| US-20230129965-A1 | HYDROPHILIC AND OLEOPHOBIC POLYMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-04-27 | — | — | US | disclosed |
| CN-106676141-B | Enzymatic preparation method of chiral intermediate (S) -3-hydroxy glutaric acid monoester | 浙江京新药业股份有限公司 | 2020-12-08 | — | — | CN | disclosed |
| CN-111518035-A | Rosuvastatin tert-butylamine salt and preparation method thereof | 安徽鼎旺医药有限公司 | 2020-08-11 | — | — | CN | disclosed |
| US-8874019-B2 | Image forming method | KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) | 2014-10-28 | — | — | US | disclosed |
| WO-2014140006-A1 | PROCESS FOR ENANTIOSELECTIVE SYNTHESIS OF 3-HYDROXY-GLUTARIC ACID MONOESTERS AND USE THEREOF | SANDOZ AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| US-20130202336-A1 | IMAGE FORMING METHOD | KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) | 2013-08-08 | — | — | US | disclosed |
| EP-1472228-B1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS | NOVARTIS AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| US-20080182873-A1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS | ACEMOGLU MURAT | 2008-07-31 | — | — | US | disclosed |
| US-7371865-B2 | Process for the manufacture of HMG-CoA reductase inhibitors | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-20050070605-A1 | Process for the manufacture of hmg-coa reductase inhibitors | ACEMOGLU MURAT (CH) | 2005-03-31 | — | — | US | disclosed |
| EP-1472228-A1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS | Novartis AG (CH) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003064392-A1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS | NOVARTIS AG (CH) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182873-A1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS | HMGCR, COASY, DHCR7 | SLC22A6 1254/4885GPR84 3272/4885MAPT 2873/4885 |
| US-20050070605-A1 | Process for the manufacture of hmg-coa reductase inhibitors | HMGCR, COASY, DHCR7 | SLC22A6 1254/4885GPR84 3272/4885MAPT 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.